X4 Pharmaceuticals/XFOR
$0.94
-2.05%-
1D1W1MYTD1YMAX
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Ticker
XFOR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Paula Ragan
Employees
93
Headquarters
Boston, United States
Website
www.x4pharma.com
XFOR Metrics
BasicAdvanced
$164M
Market cap
-
P/E ratio
-$0.70
EPS
0.38
Beta
-
Dividend rate
Price and volume
Market cap
$164M
Beta
0.38477
52-week high
$2.58
52-week low
$0.57
Average daily volume
3.4M
Financial strength
Current ratio
3.71
Long term debt to equity
5,291.892
Total debt to equity
5,291.892
Management effectiveness
Return on assets (TTM)
-108.98%
Return on equity (TTM)
-489.12%
Return on investment (TTM)
-133.2%
Valuation
Price to book
158.244
Growth
Earnings per share change (TTM)
46.95%
What the Analysts think about XFOR
Analyst Ratings
Majority rating from 6 analysts.
Price Targets
Average projection from 7 analysts.
High $5.50
Low $1.00
$0.94
Current price
$4.12
Average price target
XFOR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$52M
170.68%
Profit margin
0%
NaN%
XFOR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.33
-$0.01
-$0.10
-$0.26
-
Expected
-$0.16
-$0.15
-$0.15
-$0.16
$0.01
Surprise
102.04%
-93.28%
-34.58%
59.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for X4 Pharmaceuticals stock?
X4 Pharmaceuticals (XFOR) has a market cap of $164M as of May 17, 2024.
What is the P/E ratio for X4 Pharmaceuticals stock?
The price to earnings (P/E) ratio for X4 Pharmaceuticals (XFOR) stock is 0 as of May 17, 2024.
Does X4 Pharmaceuticals stock pay dividends?
No, X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders as of May 17, 2024.
When is the next X4 Pharmaceuticals dividend payment date?
X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders.
What is the beta indicator for X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the X4 Pharmaceuticals stock price target?
The target price for X4 Pharmaceuticals (XFOR) stock is $4.12, which is 338.3% above the current price of $0.94. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell X4 Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.